Welcome to our dedicated page for Bioharvest SEC filings (Ticker: BHST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioHarvest Sciences Inc. (NASDAQ: BHST) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer. BioHarvest files reports with the U.S. Securities and Exchange Commission that document its Botanical Synthesis biotechnology business, financial condition, and capital markets activity.
BioHarvest uses Form 6-K to furnish current reports, including unaudited interim condensed consolidated financial statements, management’s discussion and analysis for specific periods, material change reports, and news releases. These filings cover topics such as revenue trends from the VINIA nutraceutical brand, the growth of the CDMO Services division, and updates on technology initiatives like plant-based exosomes and saffron-derived compounds developed with partners.
The company also references its annual reporting on Form 40-F and a shelf registration statement on Form F-3, which supports public offerings of common stock. Related prospectus supplements and underwriting agreements are incorporated into 6-K submissions, providing detail on how BioHarvest raises capital to fund manufacturing expansion, research and development, marketing, and general corporate purposes.
On Stock Titan, AI-powered tools can help interpret BioHarvest’s filings by summarizing key points from lengthy financial statements and management discussions, highlighting items such as segment performance, non-IFRS measures like Adjusted EBITDA, and material changes reported to regulators. Users can also track ongoing 6-K submissions to follow new grants, strategic CDMO contracts, and other disclosed events that shape the company’s Botanical Synthesis and nutraceutical strategy.
BioHarvest Sciences Inc. filed its Annual Report on Form 40-F for the fiscal year ended December 31, 2025. The filing states the registrant had 22,666,842 common shares issued and outstanding as of December 31, 2025. The report incorporates the AIF, audited consolidated financial statements, MD&A and governance documents as exhibits.
The filing notes the Company is a foreign private issuer, prepares financial statements under IFRS, and did not include management's internal control attestation due to the SEC transition period for newly public companies.
BioHarvest Sciences reports that its VINIA nutraceutical line has become the #1 resveratrol polyphenol brand in the United States, based on 2025 sales versus NielsonIQ and Amazon market projections. VINIA’s position is tied to clinically demonstrated increases in arterial dilation, which improve blood flow and oxygen delivery.
The direct‑to‑consumer VINIA business generated more than $30 million in U.S. revenue for full‑year 2025 and about $85 million in global cumulative revenue to date, with roughly 80% of U.S. VINIA revenue coming through the VINIA.com website. BioHarvest cites over 85,000 active users across the United States and Israel.
The company highlights its proprietary Botanical Synthesis platform, which grows a red grape cell composition that can magnify piceid resveratrol levels by up to 100x versus natural grapes while preserving a complex of grape polyphenols. Management positions VINIA as a foundational compound for future plant‑based health products.
BioHarvest Sciences Inc. filed a Form 6-K to share that it will release its fourth quarter and full year 2025 financial results after market close on March 31, 2026. On the same day, the company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time to discuss the results and provide a business update.
The webcast will be accessible through an online registration link, with a replay later available in the Investor Relations Events & Presentations section of the company’s website. The filing also reiterates BioHarvest’s focus on its proprietary Botanical Synthesis platform and notes standard forward-looking statement cautions.
BioHarvest Sciences Inc. reported that its board approved new long‑term incentive awards for employees, officers and directors under its equity incentive plan. The package includes 516,812 stock options and 264,121 restricted share units, all granted at the March 13, 2026 closing share price.
The options have a 10‑year term, and both options and RSUs vest quarterly over three years starting March 13, 2026. The company highlights that equity‑based compensation is intended to align personnel with shareholder interests while preserving cash, supporting its strategy in botanical synthesis, nutraceutical products and CDMO services.
BioHarvest Sciences Inc. filed a report describing changes to its board of directors. The company announced that David Tsur resigned as a director after serving since 2021. It simultaneously appointed Prof. Hezi Levy to the board, effective immediately.
The filing highlights Prof. Levy’s decades of leadership in Israel’s healthcare system. He is a physician who previously served as Director General of the Israeli Ministry of Health during the COVID-19 pandemic, Head of the Medical Corps of the Israel Defense Forces with the rank of Brigadier General, and General Manager of Barzilai Medical Center.
BioHarvest Sciences Inc. filed a Form 6-K to report a Board transition. Long-serving director David Tsur is stepping down after more than four years of service, during which he supported the company’s strategic development, governance, and growth initiatives.
The company has appointed Prof. Hezi Levy to its Board of Directors, effective immediately. Prof. Levy brings decades of leadership experience across Israel’s healthcare system, including roles as Director General of the Israeli Ministry of Health, Head of the Israel Defense Forces Medical Corps, and General Manager of Barzilai Medical Center.
Chairman Zaki Rakib highlighted that Prof. Levy’s medical and executive background is expected to strengthen governance as BioHarvest scales its direct-to-consumer products and advances its biotechnology CDMO platform based on its Botanical Synthesis technology.
BioHarvest Sciences Inc. filed a Form 6-K to share a news release announcing that its management has been invited to participate in the 38th Annual Roth Conference for growth companies, held on March 22-24, 2026 at The Ritz-Carlton Laguna Niguel in Dana Point.
CEO Ilan Sobel will host one-on-one meetings with institutional investors during the event. Sobel highlighted that a successful Q4 2025 financing round left the company fully funded from a near-term capital expenditure perspective and focused on accelerating growth in both its CDMO and consumer product businesses.
The release notes that BioHarvest has over 85,000 direct customers on the product side and anchor CDMO research partnerships, supporting its goal of achieving significant growth milestones in 2026 using its patented Botanical Synthesis technology to develop plant-based compounds.
BioHarvest Sciences shares a year-end update highlighting its first full year as a Nasdaq-listed company, with an annualized revenue run rate above US$36 million and gross margins over 60%. Management describes 2025 as a year of execution and balance sheet strengthening, including raising about $30.8 million through warrant exercises, debt conversions, and an oversubscribed institutional equity financing.
The VINIA-branded direct-to-consumer line now has more than 85,000 active users, over 90% of Vinia.com sales via subscriptions, and a 4.7/5 rating from more than 10,000 reviews. The CDMO Services division signed anchor contracts across several industries, began work on two major plant-based compounds, and expects its revenues to eventually surpass the products division. The company plans to invest in a 100-ton manufacturing footprint and targets adjusted EBITDA breakeven while pursuing growth from both its D2C and CDMO businesses.